ArticlePloS one2013
Aflatoxin B1 negatively regulates Wnt/β-catenin signaling pathway through activating miR-33a.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 71 citations in OpenAlex.
- Roles of microRNAs in multiple organs under mycotoxin stress by bioinformatic analysis: microRNA regulation during mycotoxin exposure.Poultry science · 2025Review
- The Detoxification Effects of Melatonin on Aflatoxin-Caused Toxic Effects and Underlying Molecular Mechanisms.Antioxidants (Basel, Switzerland) · 2024Review
- Lycopene as a Therapeutic Agent against Aflatoxin B1-Related Toxicity: Mechanistic Insights and Future Directions.Antioxidants (Basel, Switzerland) · 2024Review
- MicroRNAs: exploring their role in farm animal disease and mycotoxin challenges.Frontiers in veterinary science · 2024Review
- Article
- Infectious Agents Induce Wnt/β-Catenin Pathway Deregulation in Primary Liver Cancers.Microorganisms · 2023Review
- The role of inflammatory and remodelling biomarkers in patients with non-small cell lung cancer.Central-European journal of immunology · 2023Article
- Aflatoxins in Feed: Types, Metabolism, Health Consequences in Swine and Mitigation Strategies.Toxins · 2022Review
- MicroRNA regulates the toxicological mechanism of four mycotoxins in vivo and in vitro.Journal of animal science and biotechnology · 2022Review
- Protective and detoxifying effects conferred by selenium against mycotoxins and livestock viruses: A review.Frontiers in veterinary science · 2022Review
- Regulatory role of miRNAs in Wnt signaling pathway linked with cardiovascular diseases.Current research in pharmacology and drug discovery · 2022Article
- Review
- Review
- Role of microRNA-33a in malignant cells.Oncology letters · 2020Review
- Risk assessment of aflatoxins in food.EFSA journal. European Food Safety Authority · 2020Article
- Contamination of Aflatoxins Induces Severe Hepatotoxicity Through Multiple Mechanisms.Frontiers in pharmacology · 2020Review
- Wnt/β-Catenin Signaling in Liver Cancers.Cancers · 2019Review
- Article
- Preparation of Anti-Human Podoplanin Monoclonal Antibody and its application in Immunohistochemical Diagnosis.Scientific reports · 2018Article
- Effective preparation of a monoclonal antibody against human chromogranin A for immunohistochemical diagnosis.BMC biotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs are known to play an important role in modulating gene expression in various diseases including cancers and cardiovascular disorders, but only a few of them are associated with the pathology of aflatoxin B1 (AFB1), a potent mycotoxin. Here, we discovered a novel regulatory network between AFB1, miR-33a and β-catenin in human carcinoma cells. The level of miR-33a was up-regulated in hepatocellular carcinoma (HCC) cells treated with AFB1, while in the same cells causing the decrease in β-catenin expression when treated at their IC50 values. miR-33a, specifically miR-33a-5p, was demonstrated to down-regulate the expression of β-catenin, affect the β-catenin pathway, and inhibit cell growth. Also, by employing a luciferase assay, we found that miR-33a down-regulated β-catenin by directly binding to the 3'-UTR of β-catenin. These results suggested that AFB1 might down-regulate β-catenin by up-regulating miR-33a. This understanding opens new lines of thought in the potential role of miR-33a in the clinical therapy of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.